Continuous infusion pentobarbital for refractory status epilepticus in children

Area of Science:

• Pediatric Neurology
• Critical Care Medicine

Background:

• Refractory status epilepticus (RSE) in children is a critical neurological emergency.
• Continuous pentobarbital therapy is a treatment option for RSE, but its dosing and outcomes require further characterization.

Purpose of the Study:

• To describe the dosing regimens used in continuous pentobarbital therapy for pediatric RSE.
• To evaluate the outcomes associated with continuous pentobarbital therapy in children with RSE.

Main Methods:

• Retrospective review of medical charts of 30 pediatric patients treated with continuous pentobarbital.
• Analysis of administered loading doses, infusion rates, and achievement of burst suppression.

Main Results:

• Patients received a mean loading dose of 5.4 mg/kg and initial infusion of 1.1 mg/kg/h, with a maximum infusion of 4.8 mg/kg/h.
• 33% achieved sustained burst suppression; 66.7% relapsed, but 60% of those eventually re-achieved it.
• Poor outcomes (death, encephalopathy) occurred in 33% of patients, with high rates of inotrope use (93%) and infections (66%).

Conclusions:

• Continuous pentobarbital therapy for pediatric RSE involves significant adverse events, including cardiovascular support needs and infections.
• While initial treatment success varies, a substantial proportion of children can achieve burst suppression with adjusted infusions.
• Thirty-three percent of patients experienced poor outcomes, highlighting the severity of RSE and the complexities of its management.